Last reviewed · How we verify

NCT02954822

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg

Completed Phase 1 Last updated 18 September 2017
What this trial tests

Phase 1 trial testing Evogliptin→Evogliptin+Glimepiride→Glimepiride in Type2 Diabetes in 36 participants. Completed in 9 August 2017.

Timeline
14 November 2016
Primary endpoint
25 January 2017
9 August 2017

Quick facts

Lead sponsorDong-A ST Co., Ltd.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposehealth services research
Enrollment36
Start date14 November 2016
Primary completion25 January 2017
Estimated completion9 August 2017
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Dong-A ST Co., Ltd. — full company profile →

Who can join

Adults 19 to 45, male only, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, open-label, multiple dosing, three treatment, three period, two sequence clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and glimepiride 4 mg after oral administration in healthy male subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
    Yoo H, Kim Y, Jang IJ, Yu KS, et al · · 2020 · cited 6× · PMID 33262578 · DOI 10.2147/dddt.s275343

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

Other Dong-A ST Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02954822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing